Workflow
Lexeo Therapeutics(LXEO) - 2023 Q4 - Annual Results
LXEOLexeo Therapeutics(LXEO)2024-03-11 20:11

Exhibit 99.1 Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights Lexeo announces 95.0Mequityfinancing,whichinadditionto2023yearendcashandcashequivalentsof95.0M equity financing, which in addition to 2023 year-end cash and cash equivalents of 121.5M, extends runway to fund operations into 2027 Reports frataxin protein expression data from a subset of the second dose cohort of SUNRISE-FA, a Phase 1/2 clinical trial of LX2006 for the treatment of Friedreich's ataxia (FA) cardiomyopathy, showing positive change in post-treatmen ...